IDNA Genomics Public Ltd (CYS:IDNA)
Cyprus · Delayed Price · Currency is EUR 10.00
-1.00 (-9.09%)
At close: Sep 21, 2026
IDNA Genomics Public Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 0.01 | 0.01 | 0.41 | 0.1 |
Cash & Short-Term Investments | 0.01 | 0.01 | 0.41 | 0.1 |
Cash Growth | -96.59% | -97.08% | 286.37% | - |
Accounts Receivable | 0.12 | 0.08 | 0.14 | 0.12 |
Other Receivables | 0.34 | 0.36 | 0.33 | 0.23 |
Receivables | 0.46 | 0.44 | 0.47 | 0.35 |
Inventory | 0.32 | 0.3 | 0.26 | 0.21 |
Total Current Assets | 0.79 | 0.75 | 1.13 | 0.66 |
Property, Plant & Equipment | 0.26 | 0.34 | 0.35 | 0.42 |
Long-Term Investments | - | - | 0.1 | 3.85 |
Goodwill | - | - | - | 1.34 |
Other Intangible Assets | - | - | 1.23 | 1.22 |
Long-Term Accounts Receivable | - | 0.04 | 0.05 | - |
Long-Term Deferred Tax Assets | 0 | 0 | 0 | 0 |
Other Long-Term Assets | 0.04 | - | - | 0.03 |
Total Assets | 1.09 | 1.14 | 2.86 | 7.52 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 1.01 | 0.96 | 0.44 | 1.37 |
Accrued Expenses | 0.04 | 0.07 | 0.07 | 0.06 |
Short-Term Debt | 1.31 | 1.43 | 1.48 | 0.22 |
Current Portion of Leases | 0.1 | 0.16 | 0.12 | 0.11 |
Other Current Liabilities | 2.39 | 1.39 | 0.3 | 0.53 |
Total Current Liabilities | 4.85 | 4.01 | 2.41 | 2.29 |
Long-Term Debt | 1.06 | 1.22 | 0.98 | 2.64 |
Long-Term Leases | 0.09 | 0.11 | 0.14 | 0.19 |
Long-Term Deferred Tax Liabilities | - | - | 0 | - |
Other Long-Term Liabilities | 0.01 | 0.01 | - | - |
Total Liabilities | 6.01 | 5.35 | 3.52 | 5.12 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-In Capital | 3.95 | 3.85 | 3.85 | 3.85 |
Retained Earnings | -3.66 | -3.15 | -0.91 | -1.47 |
Comprehensive Income & Other | -3.83 | -3.83 | -3.75 | - |
Total Common Equity | -3.51 | -3.11 | -0.79 | 2.4 |
Minority Interest | -1.4 | -1.1 | 0.12 | - |
Shareholders' Equity | -4.92 | -4.21 | -0.66 | 2.4 |
Total Liabilities & Equity | 1.09 | 1.14 | 2.86 | 7.52 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 2.56 | 2.92 | 2.71 | 3.15 |
Net Cash (Debt) | -2.56 | -2.91 | -2.31 | -3.05 |
Net Cash Growth | - | - | - | - |
Net Cash Per Share | -0.93 | -1.05 | -0.84 | -1.10 |
Filing Date Shares Outstanding | 2.76 | 2.76 | 2.76 | 2.76 |
Total Common Shares Outstanding | 2.76 | 2.76 | 2.76 | 2.76 |
Working Capital | -4.06 | -3.25 | -1.27 | -1.63 |
Book Value Per Share | -1.27 | -1.13 | -0.28 | 0.87 |
Tangible Book Value | -3.51 | -3.11 | -2.02 | -0.15 |
Tangible Book Value Per Share | -1.27 | -1.13 | -0.73 | -0.06 |
Machinery | 0.19 | 0.19 | 0.19 | 0.18 |